Searches for "peptides for hair growth" turn up long lists of compounds, but almost none of the peptides sold on the research market have been tested for hair growth at all. In this library, exactly one has any published link to the topic, and it is a passing mention in a review, not a dedicated study. This guide states that plainly rather than padding out the list.
Summary
| Compound | Best evidence | Stage |
|---|---|---|
| GHK-Cu (topical) Stocked locally | Listed among GHK-Cu's effects in a 2018 review of cell and animal work | Cell and animal only; no human hair trial found |
| GHK-Cu (injectable) Stocked locally | Same underlying cell and animal work as the topical form | Cell and animal only; the injected route also lacks the topical form's human skin studies |
| GLOW blend Stocked locally | Marketed for hair as part of a three-peptide vial | Not studied as a combination; each ingredient's own evidence is animal or cell level |
GHK-Cu: the one compound with any hair-related data
GHK-Cu is a three-amino-acid copper-binding peptide, sold both as a topical cosmetic ingredient and as an injectable research vial. The most complete summary of its research is a 2018 review in the International Journal of Molecular Sciences by Loren Pickart, who discovered the peptide, and Anna Margolina.
That review lists increased hair growth and larger hair follicles among the effects reported for GHK-Cu, alongside its better-documented work on collagen and wound repair. It does not describe a human trial measuring hair growth, hair count or follicle size. The hair claim rests on the same body of cell-culture and animal work that underlies GHK-Cu's other proposed effects, not on a study designed to test hair specifically.
This matters because GHK-Cu's actual human evidence, small 8 to 12 week cosmetic studies on skin density and wrinkles, was never designed to measure hair outcomes either. See GHK-Cu (topical) for that separate body of work.
The proposed mechanism for GHK-Cu's various claimed effects, hair included, is the same one used to explain its skin and wound-healing work: GHK binds copper tightly, copper is a cofactor for enzymes that build and cross-link collagen and elastin, and hair follicles, like skin, depend on a collagen-rich structure and a blood supply to stay active. That is a plausible rationale connecting an established mechanism to a claimed effect, not a demonstration that it happens. The 2018 review's gene-expression data, which shows GHK shifting the activity of many human genes toward repair patterns, comes from cell-line databases, not from follicles in a scalp.
What a real hair-growth trial would need to show
Trials that actually establish a hair-growth effect, the kind behind approved treatments, measure things like terminal hair count in a fixed scalp area, the ratio of hairs in active (anagen) versus resting (telogen) growth phases, and photographic or phototrichogram comparisons against a placebo group over months, not weeks. Nothing published on GHK-Cu, topical or injected, uses that kind of design. The 8 to 12 week cosmetic studies measured skin appearance, and the review's hair mention draws on separate animal and cell-culture observations. Until a study measures hair growth directly in people, "GHK-Cu grows hair" is an extrapolation, not a finding.
Does the injected route change anything?
No. Injectable GHK-Cu is the same molecule, repackaged for subcutaneous use instead of a cream. It draws on the identical review and the identical underlying animal and cell studies. What it does not have is even the topical form's small human skin studies, because no published human trial of injected GHK-Cu exists for any endpoint. Anyone choosing the injectable version over the cream for a hair-related reason is not acting on additional evidence; there is less human data behind the injection, not more. See GHK-Cu (injectable) for the full picture, including the safety questions specific to injecting a copper-based compound.
The GLOW blend's hair claim
GLOW combines GHK-Cu, BPC-157 and TB-500 in one vial and is marketed for skin, hair and tissue repair together. No study has tested this three-peptide combination for hair or for anything else. BPC-157 and TB-500 have no published hair-related research at all; their literature is about tendon, ligament and general tissue repair, covered in best peptides for injury healing. Buying the blend for a hair benefit means paying for two ingredients with no hair evidence behind them, alongside the one ingredient whose hair evidence is a single review mention.
What is missing from this list
Established, well-studied hair-loss treatments exist, minoxidil and finasteride chief among them, but neither is a peptide, and both fall outside the scope of a peptide research wiki. If a supplier lists a "hair growth peptide stack" beyond GHK-Cu, treat the hair claim as unverified until a study says otherwise; nothing else in this library's compound list has published hair-specific data.
Safety notes
The 2018 review describes GHK-Cu as used in cosmetic products for decades without reported adverse effects, but that record is about creams on skin, not injections. For the injectable form, the US FDA has listed GHK-Cu among bulk substances for compounding that may present significant safety risks, citing a possible risk of immunogenicity from aggregation and peptide-related impurities; that listing was withdrawn in April 2026, which does not amount to an approval. Anyone with Wilson's disease or another copper-handling disorder has a specific reason to be cautious with any copper-containing product, injected or topical.
Status in the Philippines
Topical GHK-Cu products are sold locally as cosmetics, regulated as such by FDA Philippines. The injectable research-vial form of GHK-Cu, and the GLOW blend that contains it, are not registered as medicines and are not scheduled controlled substances; they are sold only through research-chemical suppliers.
